TERT Promoter Mutation Analysis to Distinguish Glioma From Gliosis.

Hewer, Ekkehard; Phour, Jaison; Gutt-Will, Marielena; Schucht, Philippe; Dettmer, Matthias S; Vassella, Erik (2020). TERT Promoter Mutation Analysis to Distinguish Glioma From Gliosis. Journal of neuropathology and experimental neurology, 79(4), pp. 430-436. Oxford University Press 10.1093/jnen/nlaa004

	Text TERT Promoter Mutation Analysis to Distinguish Glioma From Gliosis.pdf - Other Restricted to registered users only Available under License Publisher holds Copyright. Download (197kB)
	Text nlaa004.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (802kB)

Among the most challenging diagnostic issues in surgical neuropathology is the distinction between scant infiltration by diffuse gliomas and reactive gliosis. The best documented ancillary marker to establish a definitive diagnosis of glioma in this setting is the identification of hotspot mutations in the isocitrate dehydrogenase 1 and 2 (IDH1/IDH2) genes, which is limited, however, by the low prevalence of these mutations in gliomas of elderly adults. Since telomerase reverse transcriptase (TERT) promoter mutations are present in the vast majority of IDH-wildtype diffuse gliomas, we hypothesized that combined analysis of IDH and TERT might overcome these limitations. For this purpose, we analyzed a series of non-neoplastic and neoplastic CNS samples for the prevalence of TERT hotspot mutations. TERT mutations were identified in none out of 58 (0%) reactive gliosis samples, and in 91 out of 117 (78%) IDH-wildtype gliomas. Based on a series of 200 consecutive diffuse gliomas, we found that IDH mutation analysis alone had a sensitivity of 28% (63% and 12%, respectively, in patients below and above age of 50) for detection of gliomas, whereas a combined analysis of IDH and TERT was 85% sensitive (87% and 84%, respectively, below and above age of 50). In sum, our findings suggest that TERT promoter mutation analysis contributes favorably to a molecular panel in cases equivocal for glioma versus gliosis on morphological grounds, especially in patients above age of 50, in which IDH analysis alone performs poorly.

Interest & Impact

Downloads

7 since deposited on 04 Mar 2020
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item